The Ozempic and Wegovy shortage that began in 2022 peaked in 2023-2024, leaving millions of patients and researchers scrambling for alternatives to semaglutide. While the official shortage has been largely resolved as of late 2024, supply disruptions, insurance denials, and cost barriers continue to make alternatives relevant. This guide covers the research landscape of semaglutide alternatives.
The Shortage Timeline
Semaglutide shortages were driven by demand far exceeding Novo Nordisk's production capacity. Timeline:
2021-2022: Ozempic (semaglutide for T2D) demand surges as off-label weight loss use takes off following social media attention.
2022-2023: FDA places Ozempic and Wegovy on the shortage list. Compounding pharmacies gain the right to produce compounded semaglutide under the shortage exception.
2023-2024: Compounded semaglutide becomes widely available through telehealth platforms and research vendors. Significant quality variation across sources.
Late 2024: FDA declares shortage resolved for Wegovy; Ozempic removed from shortage list. FDA sends warning letters to compounding pharmacies telling them to stop producing semaglutide. Research peptide vendors who carried semaglutide face increased legal pressure.
2025: Market normalizing, though cost and insurance coverage remain barriers for many patients.
Tirzepatide: The Superior Alternative
If semaglutide is unavailable, tirzepatide (Mounjaro/Zepbound) is not just an alternative — it's arguably better:
Greater weight loss: SURMOUNT trials showed 20-22% body weight reduction vs semaglutide's 14.9% in STEP trials.
Dual mechanism: GLP-1 + GIP dual agonism produces superior appetite suppression vs GLP-1 alone.
Availability: Zepbound (weight management indication) and Mounjaro (T2D) are both FDA-approved. The shortage situation for tirzepatide has been better than semaglutide.
Research availability: FelixChem and Vandl Labs carry tirzepatide for research purposes.
Retatrutide: The Next Generation
For researchers interested in next-generation GLP-1 compounds, retatrutide (LY3437943) represents the current frontier:
Triple agonism: GLP-1 + GIP + glucagon receptor activation
Phase 3 data: Approximately 24% body weight reduction — the highest ever recorded in an obesity drug trial
Not yet approved: Retatrutide is in Phase 3 clinical trials as of 2025. FDA approval is expected in 2025-2026.
Research availability: Limited but available through select vendors including Vandl Labs.
GH Peptides as Adjuncts
For researchers who want fat loss support while GLP-1 access is complicated, growth hormone secretagogue stacks offer complementary mechanisms:
CJC-1295 + Ipamorelin: The classic GH optimization stack. Elevated GH/IGF-1 promotes fat oxidation, particularly visceral fat reduction. Not as potent as GLP-1 drugs for weight loss, but significant for body recomposition.
Tesamorelin: FDA-approved specifically for visceral fat reduction in HIV lipodystrophy. Strong evidence for visceral adipose tissue (VAT) reduction.
AOD-9604 (HGH Fragment 176-191): The C-terminal fragment of HGH that retains fat-burning properties without growth effects. Weaker evidence than approved compounds but widely available.
Key Takeaways
The Ozempic shortage pushed semaglutide into the mainstream consciousness and accelerated the entire GLP-1 drug class. Tirzepatide has largely filled the gap with superior efficacy. Retatrutide represents the near-future of metabolic peptides. For ongoing monitoring of what's available and where, PeptideWiki's vendor page tracks current inventory.